Lung cancer is the most common cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for more than 85% of cases.
The current COVID-19 pandemic has introduced a number of difficulties for the management of patients with NSCLC.
Patients are at an increased risk of COVID-19 and its related complications, while the restrictions to daily life have also impacted appointment and treatment schedules and patients' mental health.
In this video, Dr Giuseppe Giaccone (Weill Cornell Medicine, New York City, USA) is joined by Dr Marina Garassino (Instituto Nazionale dei Tumori, Milan, Italy) and they discuss the management of the treatment of NSCLC patients during the COVID-19 pandemic.
This programme has been developed by M3 (EU) and funded by an unrestricted grant from Pfizer. Pfizer has had no involvement or influence on the content of this programme.